Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2011 1
2012 3
2013 4
2014 3
2015 5
2016 8
2017 12
2018 11
2019 11
2020 14
2021 9
2022 7
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.
Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Lafyatis R, Stifano G, Spotswood H, Chen-Harris H, Dziadek S, Morimoto A, Sornasse T, Siegel J, Furst DE. Khanna D, et al. Among authors: frech tm. Lancet. 2016 Jun 25;387(10038):2630-2640. doi: 10.1016/S0140-6736(16)00232-4. Epub 2016 May 5. Lancet. 2016. PMID: 27156934 Free article. Clinical Trial.
Pauling and Frech reply.
Pauling JD, Frech TM. Pauling JD, et al. Among authors: frech tm. J Rheumatol. 2019 Nov;46(11):1544-1545. doi: 10.3899/jrheum.190565. Epub 2019 Jul 15. J Rheumatol. 2019. PMID: 31308205 No abstract available.
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
Spiera R, Kuwana M, Khanna D, Hummers L, Frech TM, Stevens W, Matucci-Cerinic M, Kafaja S, Distler O, Jun JB, Levy Y, Leszcyzński P, Gordon J, Steen V, Lee EB, Jankowski T, Litinsky I, Chung L, Hsu V, Mayes M, Sandorfi N, Simms RW, Finzel S, de Vries-Bouwstra J, Constantine S, Dgetluck N, Dinh Q, Bloom BJ, Furst DE, White B, Denton CP; RESOLVE-1 Study Group. Spiera R, et al. Among authors: frech tm. Arthritis Rheumatol. 2023 Sep;75(9):1608-1618. doi: 10.1002/art.42510. Epub 2023 Jun 15. Arthritis Rheumatol. 2023. PMID: 37098795 Free article. Clinical Trial.
Novel therapies and innovation for systemic sclerosis skin ulceration.
Frech TM, Frech M, Saknite I, O'Connell KA, Ghosh S, Baba J, Tkaczyk ER. Frech TM, et al. Best Pract Res Clin Rheumatol. 2022 Dec;36(4):101813. doi: 10.1016/j.berh.2022.101813. Epub 2023 Jan 5. Best Pract Res Clin Rheumatol. 2022. PMID: 36609122 Review.
Three Distinct Transcriptional Profiles of Monocytes Associate with Disease Activity in Scleroderma Patients.
Makinde HM, Dunn JLM, Gadhvi G, Carns M, Aren K, Chung AH, Muhammad LN, Song J, Cuda CM, Dominguez S, Pandolfino JE, Dematte D'Amico JE, Budinger GS, Assassi S, Frech TM, Khanna D, Shaeffer A, Perlman H, Hinchcliff M, Winter DR. Makinde HM, et al. Among authors: frech tm. Arthritis Rheumatol. 2023 Apr;75(4):595-608. doi: 10.1002/art.42380. Epub 2023 Feb 1. Arthritis Rheumatol. 2023. PMID: 36281773 Free PMC article.
CONQUER Scleroderma: association of gastrointestinal tract symptoms in early disease with resource utilization.
Luebker S, Frech TM, Assassi S, Skaug B, Gordon JK, Lakin K, Bernstein EJ, Luo Y, Steen VD, Shah AA, Hummers LK, Richardson C, Moore DF, Khanna D, Castelino FV, Chung L, Kapoor P, Hant FN, Shanmugam VK, VanBuren JM, Alvey J, Harding M, Shah A, Makol A, Lebiedz-Odrobina D, Thomas JK, Volkmann ER, Molitor JA, Sandorfi N. Luebker S, et al. Among authors: frech tm. Rheumatology (Oxford). 2023 Oct 3;62(10):3433-3438. doi: 10.1093/rheumatology/kead176. Rheumatology (Oxford). 2023. PMID: 37079727
86 results